This site uses cookies to provide you with a more responsive and personalised service. By using this site you agree to our use of cookies. Please read our cookie notice for more information on the cookies we use and how to delete or block them.

Bookmark Email Print page

Eli Lilly

Enhancing Consumer Involvement in Medicines Health Technology Assessment


In most developed countries, including Australia, governments have introduced Health Technology Assessment (HTA) systems to help to manage the introduction, appropriate use and reimbursement of new technologies, including medicines.

Given the rapid reforms to HTA systems that are occurring, Deloitte Economics was engaged by Eli Lilly to take stock of the changes that have been implemented in a range of developed markets, including Australia, and to identify emerging ‘best practice’ approaches to enhanced consumer and community involvement in HTA.

Related links


Follow us


Talk to us